Search
for
Sort by
Research 511–540 of 1000+
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Drug pipeline 2Q22 — a downturn in approvals
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Effect of diode pumping solid state laser with wavelength 589 nm on gene expression of interlukine-2 and interferon-gamma Lowercase in human T-lymphocytes
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- ESGCT and FSGT Collaborative Congress Helsinki, Finland September 17–20, 2015 Abstracts
- Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study
- Novel drugs of United States Food and Drug Administration approved in 2024
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- HPLC Profiling and Insilco studies of Chochurus olitoris (Jute) Leave Fractions against Steroid 5α-Reductase 2 (SRD5α2)
- Resveratrol derivatives: a patent review (2009 – 2012)
- Frontal fibrosing alopecia and lichen planopilaris: epidemiology, treatment, and remission rate (2014-2024)
- Global, Regional, and National Burden of Alopecia Areata in Children and Adolescents Aged 0-19 years from 1990 to 2021 and Projection to 2040
- The Efficacy of Azelaic Acid 20% Cream in the Treatment of Scalp Alopecia Areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Ottawa, Ontario, Canada, February 13–16, 2013
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Current and future pharmacotherapy for alopecia areata
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins